Long-term safety of targeted agents used to treat metastatic renal cell carcinoma: The issue is not the rate of adverse events over time, but the expertise needed to manage them

Camillo Porta, Silvia Chiellino

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)S613-S615
JournalTranslational Cancer Research
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this